| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $9,219,271 | 8 | 18 |
Sells | $28,440,732 | 36 | 82 |
| Heron Patrick J | director | 8 | $9.22M | 0 | $0 | $9.22M |
| Fairey William | director | 0 | $0 | 1 | $155,091 | $-155,091 |
| Quan Joanne | CHIEF MEDICAL OFFICER | 0 | $0 | 2 | $793,892 | $-793,892 |
| BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | 0 | $0 | 4 | $961,929 | $-961,929 |
| Radovich Peter | PRESIDENT AND COO | 0 | $0 | 4 | $1.14M | $-1.14M |
| Brege Laura | director | 0 | $0 | 1 | $1.26M | $-1.26M |
| Ramasastry Saira | director | 0 | $0 | 7 | $1.3M | $-1.3M |
| Howe Jolanda | SVP, GLOBAL CONTROLLER | 0 | $0 | 8 | $3.56M | $-3.56M |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER | 0 | $0 | 6 | $8.16M | $-8.16M |
| GREY MICHAEL G | director | 0 | $0 | 3 | $11.1M | $-11.1M |
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Over the last 12 months, insiders at Mirum Pharmaceuticals, Inc. have bought $9.22M and sold $28.44M worth of Mirum Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Mirum Pharmaceuticals, Inc. have bought $3.54M and sold $9.71M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Heron Patrick J (director) — $9.22M.
The last purchase of 131,425 shares for transaction amount of $9M was made by Heron Patrick J (director) on 2026‑01‑23.
| 2026-02-13 | Sale | Ramasastry Saira | director | 2,000 0.0038% | $102.09 | $204,180 | -1.14% | |
| 2026-02-02 | Sale | Peetz Christopher | CHIEF EXECUTIVE OFFICER | 9,108 0.0175% | $103.30 | $940,888 | -1.44% | |
| 2026-02-02 | Sale | Radovich Peter | PRESIDENT AND COO | 2,631 0.0051% | $103.30 | $271,792 | -1.44% | |
| 2026-02-02 | Sale | Howe Jolanda | SVP, GLOBAL CONTROLLER | 968 0.0019% | $103.30 | $99,998 | -1.44% | |
| 2026-01-26 | Sale | Peetz Christopher | CHIEF EXECUTIVE OFFICER | 6,831 0.0131% | $96.19 | $657,088 | +4.13% | |
| 2026-01-26 | Sale | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | 1,053 0.002% | $96.19 | $101,290 | +4.13% | |
| 2026-01-26 | Sale | Radovich Peter | PRESIDENT AND COO | 3,143 0.006% | $96.19 | $302,331 | +4.13% | |
| 2026-01-26 | Sale | Howe Jolanda | SVP, GLOBAL CONTROLLER | 842 0.0016% | $96.19 | $80,994 | +4.13% | |
| 2026-01-23 | Heron Patrick J | director | 131,425 0.1847% | $68.48 | $9M | +6.73% | ||
| 2026-01-22 | Sale | Peetz Christopher | CHIEF EXECUTIVE OFFICER | 7,098 0.0133% | $93.33 | $662,422 | +9.73% | |
| 2026-01-22 | Sale | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | 1,421 0.0027% | $93.33 | $132,615 | +9.73% | |
| 2026-01-22 | Sale | Radovich Peter | PRESIDENT AND COO | 2,382 0.0045% | $93.33 | $222,301 | +9.73% | |
| 2026-01-22 | Sale | Quan Joanne | CHIEF MEDICAL OFFICER | 1,822 0.0034% | $93.33 | $170,039 | +9.73% | |
| 2026-01-22 | Sale | Howe Jolanda | SVP, GLOBAL CONTROLLER | 926 0.0017% | $93.33 | $86,419 | +9.73% | |
| 2026-01-20 | Sale | Quan Joanne | CHIEF MEDICAL OFFICER | 6,911 0.0131% | $90.27 | $623,853 | +9.75% | |
| 2026-01-15 | Sale | Ramasastry Saira | director | 2,000 0.004% | $90.99 | $181,980 | +9.22% | |
| 2025-12-22 | Sale | Ramasastry Saira | director | 5,000 0.01% | $80.00 | $400,000 | +14.29% | |
| 2025-12-19 | Sale | GREY MICHAEL G | director | 50,000 0.1016% | $78.00 | $3.9M | +19.18% | |
| 2025-12-18 | Sale | Ramasastry Saira | director | 2,000 0.004% | $69.73 | $139,460 | +31.82% | |
| 2025-12-01 | Sale | GREY MICHAEL G | director | 50,000 0.1071% | $74.00 | $3.7M | +29.33% |
| Heron Patrick J | director | 459010 0.9144% | $40.32M | 16 | 0 | +4.03% |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER | 160294 0.3193% | $14.08M | 4 | 15 | +41.16% |
| BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | 43741 0.0871% | $3.84M | 3 | 4 | +37.06% |
| Radovich Peter | PRESIDENT AND COO | 20655 0.0411% | $1.81M | 0 | 14 | |
| Brege Laura | director | 15703 0.0313% | $1.38M | 1 | 1 | +63.65% |
| Quan Joanne | CHIEF MEDICAL OFFICER | 12817 0.0255% | $1.13M | 0 | 3 | |
| Howe Jolanda | SVP, GLOBAL CONTROLLER | 4503 0.009% | $395,543.52 | 0 | 18 | |
| Fairey William | director | 2500 0.005% | $219,600.00 | 0 | 1 | |
| GREY MICHAEL G | director | 0 0% | $0 | 0 | 6 | |
| Ramasastry Saira | director | 0 0% | $0 | 0 | 8 | |
| BARRIS PETER J | 10 percent owner | 4186243 8.3394% | $367.72M | 1 | 0 | +5.09% |
| MOTT DAVID M | 10 percent owner | 4186243 8.3394% | $367.72M | 1 | 0 | +5.09% |
| MAKOWER JOSHUA | 10 percent owner | 4186243 8.3394% | $367.72M | 1 | 0 | +5.09% |
| SANDELL SCOTT D | 10 percent owner | 4186243 8.3394% | $367.72M | 1 | 0 | +5.09% |
| BASKETT FOREST | 10 percent owner | 4186243 8.3394% | $367.72M | 1 | 0 | +5.09% |
| Walker Paul Edward | 10 percent owner | 4186243 8.3394% | $367.72M | 1 | 0 | +5.09% |
| Sonsini Peter W. | 10 percent owner | 4186243 8.3394% | $367.72M | 1 | 0 | +5.09% |
| Florence Anthony A. Jr. | 10 percent owner | 4186243 8.3394% | $367.72M | 1 | 0 | +5.09% |
| Behbahani Ali | 10 percent owner | 4186243 8.3394% | $367.72M | 1 | 0 | +5.09% |
| Makhzoumi Mohamad | 10 percent owner | 4186243 8.3394% | $367.72M | 1 | 0 | +5.09% |
| New Enterprise Associates 16, L.P. | 10 percent owner | 4186243 8.3394% | $367.72M | 1 | 0 | +5.09% |
| Chang Carmen | 10 percent owner | 4186243 8.3394% | $367.72M | 1 | 0 | +5.09% |
| Frazier Life Sciences IX, L.P. | 10 percent owner | 3566912 7.1056% | $313.32M | 1 | 0 | +5.09% |
| Novo Holdings A/S | 10 percent owner | 2445147 4.871% | $214.78M | 1 | 0 | +5.09% |
| O'Donnell Niall | director | 1621118 3.2294% | $142.4M | 1 | 3 | +5.09% |
| Deerfield Healthcare Innovations Fund, L.P. | 1540190 3.0682% | $135.29M | 0 | 1 | ||
| Longpre Lara | CHIEF DEVELOPMENT OFFICER | 104407 0.208% | $9.17M | 1 | 5 | +63.65% |
| Tucker Edwin Jonathan | Chief Medical Officer | 45768 0.0912% | $4.02M | 2 | 1 | +71.87% |
| Vig Pamela | CHIEF SCIENTIFIC OFFICER | 27406 0.0546% | $2.41M | 1 | 6 | +53.04% |
| Clements Ian | Chief Financial Officer | 18561 0.037% | $1.63M | 4 | 1 | +42.68% |
| Fischer Laurent | director | 6750 0.0134% | $592,920.00 | 5 | 0 | +66.98% |
| Flynn James E | 10 percent owner | 0 0% | $0 | 1 | 4 | +5.09% |
$159,914,414 | 243 | 18.52% | $3.62B | |
$66,736,176 | 136 | 27.54% | $4.06B | |
$193,151,375 | 134 | 8.18% | $4.5B | |
$52,263,649 | 70 | 1.18% | $3.74B | |
Mirum Pharmaceuticals, Inc. (MIRM) | $224,382,625 | 44 | 27.62% | $4.41B |
$477,065,869 | 34 | 82.05% | $5.44B | |
$1,275,975,557 | 32 | 19.44% | $3.79B | |
$61,717,660 | 28 | 36.84% | $3.78B | |
$150,253,463 | 26 | -52.83% | $3.54B | |
$27,105,902 | 21 | -16.06% | $4.81B | |
$57,686,748 | 13 | 21.11% | $5.24B | |
$91,269,919 | 12 | 12.86% | $3.99B | |
$2,477,801 | 11 | 4.98% | $4.72B | |
$3,073,199 | 10 | 16.77% | $5.33B | |
$1,711,150 | 9 | 31.59% | $3.64B | |
$25,064,843 | 9 | 12.75% | $4.71B | |
$2,246,813 | 6 | 70.15% | $4.61B | |
$50,990,767 | 2 | 19.79% | $3.89B | |
$7,600,000 | 1 | -4.05% | $4.99B |
| Increased Positions | 167 | +57.99% | 9M | +15.42% |
| Decreased Positions | 124 | -43.06% | 4M | -7.7% |
| New Positions | 64 | New | 3M | New |
| Sold Out Positions | 44 | Sold Out | 1M | Sold Out |
| Total Postitions | 331 | +14.93% | 61M | +7.72% |
| Frazier Life Sciences Management, L.P. | $530,495.00 | 13.07% | 6.8M | 0 | 0% | 2025-09-30 |
| Janus Henderson Group Plc | $390,162.00 | 9.61% | 5M | -238,691 | -4.56% | 2025-09-30 |
| Blackrock, Inc. | $281,242.00 | 6.93% | 3.6M | +25,343 | +0.71% | 2025-09-30 |
| Vanguard Group Inc | $198,717.00 | 4.89% | 2.55M | -19,500 | -0.76% | 2025-09-30 |
| Eventide Asset Management, Llc | $196,936.00 | 4.85% | 2.52M | -114,922 | -4.36% | 2025-09-30 |
| Bvf Inc/Il | $116,737.00 | 2.88% | 1.5M | -1M | -45.85% | 2025-09-30 |
| State Street Corp | $105,153.00 | 2.59% | 1.35M | -28,724 | -2.09% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $100,186.00 | 2.47% | 1.28M | -133,927 | -9.45% | 2025-09-30 |
| Novo Holdings A/S | $98,683.00 | 2.43% | 1.26M | -236,027 | -15.73% | 2025-09-30 |
| Tang Capital Management Llc | $96,497.00 | 2.38% | 1.24M | 0 | 0% | 2025-09-30 |